Shots: The company has reported the expansion of P-III PREVENT-19 pivotal trial to evaluate the efficacy, safety, and immunogenicity of NVX-CoV2373 vs PBO in ~3,000 adolescents aged 12-17yrs. against COVID […]readmore
Tags : Clinical Trial
Shots: The P-II/III study involves assessing of CT-P59 (40mg/kg, 80mg/kg) vs PBO in 327 patients with mild-to-mod. symptoms of COVID-19 Results: reduction in progression rates (54% for mild-to-mod. patients & […]readmore
Clinical Trials
COVID-19
Tiziana Completes Clinical Trial of Nasally Administered Foralumab for COVID-19
Shots: Tiziana has completed its clinical study in Brazil assessing nasally administered Foralumab either alone or in combination with orally administered dexamethasone in COVID-19 patients The study enrolled 39 patients […]readmore
Shots: The companies initiated the P-II study of their COVID-19 vaccine in China. The trial will generate data to support the BLA filing for approval of the vaccine in China […]readmore
Shots: J&J has resumed recruitment, enrolment, and vaccination in all studies of its COVID-19 vaccine across the EU, after a temporary pause. Trials in the US, South Africa, and some […]readmore
Shots: The P-II ROCCELLA is a dose-ranging trial involves assessing GLPG1972/S201086 (PO, qd) in three different doses vs PBO in 932 patients with knee OA for 52wks. across 12 countries […]readmore
Shots: The initiation of the post-exposure prophylaxis clinical trial follows Korean MFDS’ IND approval on Oct 08, 2020 The study will assess the preventive effect & safety of CT-P59 in […]readmore
Clinical Trials
Pharma
Strata Oncology Collaborates with Mirati Therapeutics to Broaden Enrollment in
Shots: The multiple expansion cohort will assess the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in patients with advanced solid tumors harboring a KRAS G12C mutation […]readmore
Shots: The P-I study will evaluate the safety and immunogenicity of the vaccine as well as confirm dose selection in ~144 healthy subjects aged 18-55 and >55 yrs. As part […]readmore
Shots: Ascentage will be responsible to sponsor the P-Ib/II trial (NCT03611868) which involves assessing of APG-115 in combination with Keytruda, to evaluate its safety and efficacy in solid tumors (i,e., […]readmore